Ask AI

From All Angles: Minimizing CMV in High-risk Kidney Transplant Recipients

Learn to apply best practices in antiviral protocols and clinical pathways for cytomegalovirus (CMV) prevention in high-risk kidney transplant recipients based on the latest developments and clinical data along with how to design effective antiviral regimens for kidney transplant recipients at high risk for CMV disease while minimizing drug toxicity.

Share

Program Content

Events

Activities

Refractory CMV
A Roadmap for Managing Refractory CMV
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 30, 2025

Provided by

ProCE Banner
ProCE Banner

Provided by Clinical Care Options, LLC, in collaboration with ProCE and in partnership with the American Kidney Fund

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Partners

American Kidney Fund

ProCE Banner